AREN0533 Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Robert Fallon, MD
Primary Investigator
Brief description of study
The overall goal of this study is to find out if subjects with Wilms tumor that has spread only to their lungs can be treated without having radiation therapy to their lungs.
Detailed description of study
The aims of this study are to determine the 4-year event-free survival (EFS) of patients with stage IV favorable histology (FH) Wilms' tumor with pulmonary metastases only who have complete resolution of pulmonary lesions without whole lung irradiation treated with DD4A chemotherapy comprising vincristine, dactinomycin, and doxorubicin hydrochloride, to determine the 4-year EFS of these patients who do not have resolution of pulmonary metastases by week 6 treated with the addition of cyclophosphamide and etoposide to a modified-regimen DD4A (regimen M), and to determine the 4-year EFS of patients with stage III or IV FH Wilms' tumor with loss of heterozygosity for chromosomes 1p and 16q treated with regimen M.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Wilms Tumor
-
Age: 29 years or below
-
Gender: All
